Elezanumab, CAS 1791416-49-3

Product Description: Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism[1][2].

Applications: Metabolism-protein/nucleotide metabolism

Formula: N/A

References: [1]Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492./[2]Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492./[3]Peer B Jacobson, et al. Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. Neurobiol Dis. 2021 Jul;155:105385.

CAS Number: 1791416-49-3

Molecular Weight: N/A

Compound Purity: 99.69

Research Area: Metabolic Disease

Solubility: H2O

Target: TGF-beta/Smad

• Artikelnummer: MEXHY-P99359-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99359-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK